KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
1.175
-0.175 (-12.96%)
At close: Jul 10, 2026, 4:00 PM EDT
1.210
+0.035 (2.98%)
After-hours: Jul 10, 2026, 5:51 PM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
21.84M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Evaxion | 7.53M |
| Plus Therapeutics | 5.18M |
| Marker Therapeutics | 3.55M |
| IGC Pharma | 1.11M |
KALA News
- 4 weeks ago - KALA BIO Registration statement: Registration filing - Filings
- 2 months ago - KALA BIO Quarterly report: Q1 2026 - Filings
- 2 months ago - Kala Bio falls -21.7% - TheFly
- 2 months ago - Kala Bio files $350M mixed securities shelf - TheFly
- 2 months ago - Kala Bio announces reverse stock split - TheFly
- 2 months ago - KALA BIO Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - KALA BIO Registration statement: Registration filing - Filings
- 2 months ago - Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine - TheFly